In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin - PubMed

In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin

A S Hawes et al. Infect Immun. 1992 Jul.

Abstract

The endogenous adrenocortical response to sepsis is critical for host survival. The in vivo interactions among the endogenous glucocorticoid response, the induction of cytokines, and host survival during endotoxemia were explored in this study by use of the glucocorticoid receptor antagonist RU 486. Male Lewis rats underwent sterile insertion of a right jugular venous catheter. After a 72-h recovery period, animals received a 50% lethal dose of Escherichia coli endotoxin (2.5 mg/kg) via the catheter after pretreatment for 30 min prior to lipopolysaccharide (LPS) treatment with (i) vehicle alone intravenously (i.v.) (-corticosterone [-Cort]/-RU 486/+LPS) (n = 10), (ii) the antiglucocorticoid RU 486 (10 mg/kg) i.v. (-Cort/+RU 486/+LPS) (n = 11), or (iii) RU 486 (10 mg/kg) i.v. in animals that had undergone subcutaneous implantation of a corticosterone pellet at the time of catheter insertion (+Cort/+RU 486/+LPS) (n = 10). Except in animals receiving corticosterone pretreatment, baseline plasma corticosterone levels were low in all groups. Plasma corticosterone levels increased significantly (P less than 0.001) above the baseline following LPS administration. Animals in the -Cort/+RU 486/+LPS-treated group exhibited significantly increased mortality (P less than 0.001), with only 9% of the animals surviving at 72 h, as well as significantly increased plasma interleukin-6 levels, compared with animals receiving the vehicle alone (-Cort/-RU 486/+LPS), which showed 50% mortality. Pretreatment with corticosterone and RU 486 (+Cort/+RU 486/+LPS) significantly (P less than 0.001) reversed the mortality observed with RU 486 pretreatment alone (-Cort/+RU 486/+LPS), with 70% of the animals surviving at 72 h, and significantly attenuated the peak plasma tumor necrosis factor and interleukin-6 responses to LPS, compared with those in the animals treated with vehicle alone. These data demonstrate that the blockade of glucocorticoid binding by RU 486 increases LPS-induced mortality. The reversal of this effect by the induction of hypercorticosteronemia prior to RU 486 and LPS exposure (+Cort/+RU 486/+LPS) improves survival and is further associated with significant attenuation of cytokine production. Therefore, these data suggest that the protective effect of the endogenous glucocorticoid response to acute endotoxemia may result from the down-regulation of a potentially lethal cytokine response.

Similar articles

• Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo.

  Szabó C, Thiemermann C, Wu CC, Perretti M, Vane JR. Szabó C, et al. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):271-5. doi: 10.1073/pnas.91.1.271. Proc Natl Acad Sci U S A. 1994. PMID: 7506416 Free PMC article.

• Human recombinant interleukin-1 receptor antagonist prevents adrenocorticotropin, but not interleukin-6 responses to bacterial endotoxin in rats.

  Schotanus K, Tilders FJ, Berkenbosch F. Schotanus K, et al. Endocrinology. 1993 Dec;133(6):2461-8. doi: 10.1210/endo.133.6.8243265. Endocrinology. 1993. PMID: 8243265

• Effects of endogenous glucocorticoid secretion on the interleukin-6 response to bacterial endotoxin in pregnant and non-pregnant rats.

  Cui K, Luheshi GN, Boksa P. Cui K, et al. J Endocrinol. 2011 Apr;209(1):95-103. doi: 10.1530/JOE-10-0436. Epub 2011 Jan 17. J Endocrinol. 2011. PMID: 21242229

• Choice of bacteria in animal models of sepsis.

  Cross AS, Opal SM, Sadoff JC, Gemski P. Cross AS, et al. Infect Immun. 1993 Jul;61(7):2741-7. doi: 10.1128/iai.61.7.2741-2747.1993. Infect Immun. 1993. PMID: 8514375 Free PMC article. Review. No abstract available.

Cited by

• Glucocorticoids exert opposing effects on macrophage function dependent on their concentration.

  Lim HY, Müller N, Herold MJ, van den Brandt J, Reichardt HM. Lim HY, et al. Immunology. 2007 Sep;122(1):47-53. doi: 10.1111/j.1365-2567.2007.02611.x. Epub 2007 Apr 23. Immunology. 2007. PMID: 17451463 Free PMC article.

• Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases.

  Fantuzzi G, Ghezzi P. Fantuzzi G, et al. Mediators Inflamm. 1993;2(4):263-70. doi: 10.1155/S0962935193000365. Mediators Inflamm. 1993. PMID: 18475532 Free PMC article.

• NETWORKS, BIOLOGY AND SYSTEMS ENGINEERING: A CASE STUDY IN INFLAMMATION.

  Foteinou PT, Yang E, Androulakis IP. Foteinou PT, et al. Comput Chem Eng. 2009 Dec 10;33(12):2028-2041. doi: 10.1016/j.compchemeng.2009.06.027. Comput Chem Eng. 2009. PMID: 20161495 Free PMC article.

• Glucocorticoids and TNFalpha interact cooperatively to mediate sepsis-induced leucine resistance in skeletal muscle.

  Lang CH, Frost RA. Lang CH, et al. Mol Med. 2006 Nov-Dec;12(11-12):291-9. doi: 10.2119/2006–00071.Lang. Mol Med. 2006. PMID: 17380194 Free PMC article.

• In silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammation.

  Foteinou PT, Calvano SE, Lowry SF, Androulakis IP. Foteinou PT, et al. PLoS One. 2009;4(3):e4706. doi: 10.1371/journal.pone.0004706. Epub 2009 Mar 10. PLoS One. 2009. PMID: 19274080 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central